U.S. markets open in 4 hours 58 minutes
  • S&P Futures

    4,156.50
    +9.75 (+0.24%)
     
  • Dow Futures

    32,820.00
    +63.00 (+0.19%)
     
  • Nasdaq Futures

    13,281.25
    +52.50 (+0.40%)
     
  • Russell 2000 Futures

    1,925.30
    +3.50 (+0.18%)
     
  • Crude Oil

    88.61
    -0.40 (-0.45%)
     
  • Gold

    1,791.30
    +0.10 (+0.01%)
     
  • Silver

    20.04
    +0.20 (+1.00%)
     
  • EUR/USD

    1.0193
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    2.8400
    0.0000 (0.00%)
     
  • Vix

    21.85
    +0.41 (+1.91%)
     
  • GBP/USD

    1.2088
    +0.0017 (+0.14%)
     
  • USD/JPY

    135.0100
    +0.0400 (+0.03%)
     
  • BTC-USD

    23,877.39
    +888.98 (+3.87%)
     
  • CMC Crypto 200

    553.75
    +18.52 (+3.46%)
     
  • FTSE 100

    7,457.46
    +17.72 (+0.24%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Analysts Cuts Price Target On MacroGenics - Read Why

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BMO Capital Markets downgraded MacroGenics Inc (NASDAQ: MGNX) to Market Perform following the discontinuation of enoblituzumab (B7H3 antibody) for head and neck cancers.

  • The analyst said that enoblituzumab was not a meaningful contributor to the last valuation.

  • The update has eroded confidence in MacroGenics's ability to address the unresolved safety issues with MCG018 (B7H3 ADC).

  • The company's platform has delivered several clinically active molecules and one commercial program in Margenza.

  • Related: Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study.

  • The analyst says that no program appears to stand out as a necessary value driver over the next 12-18 months. BMO lowered the price target to $4 from $31.

  • JMP Securities also lowered the price target to $20 from $24 by removing enoblituzumab. The analyst notes that there is no read-across to the B7-H3 targeting ADC MGC018, which will provide data in 2H22.

  • Price Action: MGNX shares are up 0.70% at $3.58 during the market session on the last check Tuesday.

Latest Ratings for MGNX

Date

Firm

Action

From

To

Feb 2022

Citigroup

Upgrades

Neutral

Buy

Feb 2022

SVB Leerink

Maintains

Outperform

Feb 2022

BMO Capital

Initiates Coverage On

Outperform

View More Analyst Ratings for MGNX

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.